康寧傑瑞製藥-B(09966.HK):將於2023年ESMO大會上展示KN046及KN026研究進展
格隆匯8月10日丨康寧傑瑞製藥-B(09966.HK)發佈公吿,KN046及KN026六個不同的研究進展將以摘要及壁報形式於2023年歐洲腫瘤內科學會大會(“2023年ESMO大會”)上展示,ESMO大會為一個具影響力的歐洲腫瘤學平台,為來自世界各地的臨牀醫生、研究人員、患者倡議者、記者及醫療行業代表而設計。2023年ESMO大會將於2023年10月20日至2023年10月24日(當地時間)於西班牙馬德里舉行,宣傳來自全世界的最新頂尖數據。KN046及KN026的研究進展亦將於公司網站 http:// www.alphamabonc.com 相應公佈。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.